Renal dysfunction with telaprevir in combination with peginterferon alfa-2b and ribavirin therapy

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C

“…In TVR trials, rash, anaemia, pruritus, nausea and diarrhoea were found to develop more frequently in individuals who received PEG‐IFN and RBV along with TVR than in those individuals who received PEG‐IFN and RBV only . In addition, a renal functional disorder associated with TVR therapy became evident in Japan after the Ministry of Health, Labour and Welfare approved the use of TVR . RBV is excreted in the urine, and diminished renal function can interfere with its metabolism .…”

Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C

“…In the phase III studies, a striking benefit was observed in terms of a sustained virological response, at the expense of more frequent and more severe adverse effects, including incremental anaemia, skin reactions and gastrointestinal side effects with TVR [3,4], causing premature treatment discontinuation in 10-15% of both naive and treatment-experienced patients [3,4]. Renal failure, initially ignored in the main phase III studies, was first described in Japan with triple therapy including TVR in 17 patients of a phase III trial and in 25 patients after marketing [5], and was then reported in a German cohort of patients treated under real-life conditions with triple therapy including boceprevir or TVR (in 4.7 and 6.6% of cases, respectively) [6]. The aim of this study is to report, under real-life conditions, the prevalence, consequences and predictability of TVR-associated renal failure in a French cohort of patients treated in general hospitals.…”